Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of MYGN is 8.1 and suggests 80% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell